--- title: "Weekly Recap | bioAffinity Tech -47.94%, regains Nasdaq bid compliance then fades" type: "News" locale: "en" url: "https://longbridge.com/en/news/298799543.md" description: "bioAffinity Tech (BIAF) fell 47.94% this week, closing at $7.95 and underperforming the S&P 500 by about 47.14 percentage points. The move was a spike-and-fade pattern: Tuesday (Sep 8) gapped down from $15.27 to open at $10.63 and hit an intraday low of $8.36; Wednesday briefly rebounded to a weekly high of $12.32, then slid over the next two sessions, touching $7.82 on Friday before settling at $7.95. Average daily volume was about 3." datetime: "2026-09-12T07:47:08.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/298799543.md) - [en](https://longbridge.com/en/news/298799543.md) - [zh-HK](https://longbridge.com/zh-HK/news/298799543.md) generator: "portal-rs" --- # Weekly Recap | bioAffinity Tech -47.94%, regains Nasdaq bid compliance then fades ## The Week bioAffinity Tech (BIAF) fell 47.94% this week, closing at $7.95 and underperforming the S&P 500 by about 47.14 percentage points. The move was a spike-and-fade pattern: Tuesday (Sep 8) gapped down from $15.27 to open at $10.63 and hit an intraday low of $8.36; Wednesday briefly rebounded to a weekly high of $12.32, then slid over the next two sessions, touching $7.82 on Friday before settling at $7.95. Average daily volume was about 3.62m shares, far above the median of roughly 289k, reflecting heavy turnover. ## Key Events The two main storylines were Nasdaq compliance and the AI diagnostics volume figure. In Tuesday’s pre-market session the stock was already down 25.03%, and intraday it fell as much as 38.80%; an EFFECT filing landed that day. On Wednesday (Sep 9), bioAffinity Technologies said it had regained compliance with Nasdaq’s minimum bid-price requirement after the share price recovered, and the stock surged over 30% intraday. On Thursday (Sep 10) after hours, the company reported Q2 lung test volume up 219% year on year, and the stock rose over 8% in post-market. By Friday, that AI diagnostics growth could not hold the gains: shares dropped 8.27%, suggesting profit-taking or unease about penny-stock volatility. ## Analyst Ratings Only one institution currently rates the stock, with a hold rating and no buy, overweight, underweight or sell ratings. The consensus recommendation is hold, and the consensus target price of $2,700.00135 sits roughly 33,862% above the spot price of $7.95. The high-low target range is equally $2,700.001, so there is no dispersion among analysts. Coverage ranks 489 out of 506 in the biotechnology industry. ## The Week Ahead The macro calendar starts on Tuesday (Sep 15) with the US Empire State manufacturing index, prior 20.6 and forecast 14.75. On Sep 16 a batch of US data arrives, including retail sales, retail sales ex-autos, import price index and the NAHB housing market index; retail figures will be watched for any sign of consumer resilience. No company earnings are currently scheduled, so the focus will be on whether Nasdaq compliance holds and whether trading volume settles back from this week’s spike. ## In Short The central tension this week: bioAffinity regained Nasdaq compliance and reported a 216% year-on-year jump in AI-driven lung test volume, which are positive fundamental signals; yet the stock still lost nearly 48% and lagged the S&P 500 by about 47 points. The latest session showed large-lot outflow exceeding inflow, and the stock’s penny-stock profile—price-to-book around 1.25x and market value near $4.7m—amplifies swings. Going forward, watch whether volume normalises from this week’s extreme levels and how compliance and the growth trajectory hold up alongside next week’s macro releases. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [BIAF.US](https://longbridge.com/en/quote/BIAF.US.md) ## Related News & Research - [bioAffinity Technologies wins Japan patent allowance for CyPath Lung AI algorithm](https://longbridge.com/en/news/301272577.md) - [bioAffinity Technologies Hosts CHEST Presentation on CyPath Lung Cancer Risk Assessment](https://longbridge.com/en/news/301975278.md) - [OmniAb Highlights $3B Milestone Pipeline, AI Antibody Platform at Conference](https://longbridge.com/en/news/302976846.md) - [Greenbrier (GBX) to report earnings tomorrow: here is what to expect](https://longbridge.com/en/news/302976097.md) - [Amazon.com, Inc. $AMZN Stock Sold by Cohen Klingenstein LLC](https://longbridge.com/en/news/302980467.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**